ECSP088506A - Derivados de tiadiazol como agentes antidiabeticos - Google Patents

Derivados de tiadiazol como agentes antidiabeticos

Info

Publication number
ECSP088506A
ECSP088506A EC2008008506A ECSP088506A ECSP088506A EC SP088506 A ECSP088506 A EC SP088506A EC 2008008506 A EC2008008506 A EC 2008008506A EC SP088506 A ECSP088506 A EC SP088506A EC SP088506 A ECSP088506 A EC SP088506A
Authority
EC
Ecuador
Prior art keywords
compounds
diseases
inhibitors
formula
treatment
Prior art date
Application number
EC2008008506A
Other languages
English (en)
Inventor
Thalaththani Ralalage Vedananda
Gregory Raymond Bebernitz
David Barnes
Gary Mark Coppola
Katsumasa Nakajima
Sidney Wolf Topiol
James Richard Wareing
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088506(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088506A publication Critical patent/ECSP088506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de la Fórmula son inhibidores de las fosfatasas de proteína tirosina (PTPasas), y por lo tanto, se pueden emplear para el tratamiento de las condiciones mediadas por la actividad de la PTPasa. Los compuestos de la presente invención también se pueden emplear como inhibidores de otras enzimas caracterizadas por una región de enlace de fosfotirosina, tal como el dominio SH2. De acuerdo con lo anterior, los compuestos de la Fórmula (I) se pueden emplear para la prevención y/o el tratamiento de resistencia a la insulina asociada con obesidad, intolerancia a la glucosa, diabetes mellitus, hipertensión y enfermedades isquémicas de los vasos sanguíneos grandes y pequeños, condiciones que acompañan a la diabetes tipo 2, incluyendo hiperlipidemia, hipertrigliceridemia, ateroesclerosis, restenosis vascular, síndrome de intestino irritable, pancreatitis, tumores de células adiposas y carcinomas, tales como liposarcoma, dislipidemia, y otros trastornos en donde se indique la resistencia a la insulina. En adición, los compuestos de la presente invención se pueden emplear para tratar y/o prevenir cáncer, osteoporosis, enfermedades neurodegenerativas e infecciosas, y enfermedades que involucren inflamación y al sistema inmune.
EC2008008506A 2005-12-08 2008-06-06 Derivados de tiadiazol como agentes antidiabeticos ECSP088506A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74857305P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
ECSP088506A true ECSP088506A (es) 2008-07-30

Family

ID=37950917

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008506A ECSP088506A (es) 2005-12-08 2008-06-06 Derivados de tiadiazol como agentes antidiabeticos

Country Status (26)

Country Link
US (1) US7700633B2 (es)
EP (1) EP1963292B1 (es)
JP (1) JP2009519248A (es)
KR (1) KR20080074969A (es)
CN (1) CN101326173A (es)
AR (1) AR056838A1 (es)
AT (1) ATE546440T1 (es)
AU (1) AU2006321905B2 (es)
BR (1) BRPI0619600A2 (es)
CA (1) CA2629857A1 (es)
CR (1) CR10049A (es)
EC (1) ECSP088506A (es)
ES (1) ES2381280T3 (es)
IL (1) IL191549A0 (es)
MA (1) MA30202B1 (es)
NO (1) NO20083031L (es)
NZ (1) NZ568243A (es)
PE (2) PE20071031A1 (es)
PL (1) PL1963292T3 (es)
PT (1) PT1963292E (es)
RU (1) RU2008127254A (es)
TN (1) TNSN08249A1 (es)
TW (1) TW200732315A (es)
UA (1) UA94724C2 (es)
WO (1) WO2007067615A2 (es)
ZA (1) ZA200804074B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630448A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
CA2629819A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
CN110536685A (zh) 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
BR112021012311A2 (pt) 2018-12-21 2021-09-08 Crystal Pharma, S.A.U. Uso de um composto intermediário, processo para preparar voxelotor e composto intermediário
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
EP4073242A4 (en) 2019-12-12 2024-01-03 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
EP4077319A1 (en) * 2019-12-20 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase degraders and methods of use thereof
WO2022192598A1 (en) * 2021-03-11 2022-09-15 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4359409A1 (en) * 2021-06-21 2024-05-01 Calico Life Sciences LLC Degrader compounds and uses thereof
WO2023086498A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150535A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
PE20250780A1 (es) * 2022-02-02 2025-03-14 Nerio Therapeutics Inc Inhibidores de proteina tirosina fosfatasa y usos de estos
CN119790052A (zh) * 2022-09-13 2025-04-08 金橘生物科技公司 苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) * 2023-04-28 2024-10-29 中科中山药物创新研究院 噻二唑烷酮衍生物及其制备方法和应用
CN116496248B (zh) * 2023-05-06 2025-09-02 江苏艾科姆检测有限公司 一种溴氰虫酰胺杂质的合成方法
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
AU2024288616A1 (en) * 2023-07-11 2026-02-12 Shenzhen Zhongge Biological Technology Co., Ltd. Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100868587B1 (ko) * 2002-04-03 2008-11-12 노파르티스 아게 Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
EP1594497B1 (en) * 2002-12-30 2009-05-27 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
CA2630448A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
CA2629819A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
CA2647472A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20071031A1 (es) 2007-11-15
EP1963292A2 (en) 2008-09-03
TW200732315A (en) 2007-09-01
US7700633B2 (en) 2010-04-20
ZA200804074B (en) 2009-03-25
PE20100733A1 (es) 2010-10-29
NZ568243A (en) 2011-07-29
NO20083031L (no) 2008-08-28
PT1963292E (pt) 2012-05-10
ATE546440T1 (de) 2012-03-15
JP2009519248A (ja) 2009-05-14
ES2381280T3 (es) 2012-05-24
EP1963292B1 (en) 2012-02-22
CR10049A (es) 2008-08-25
US20080262050A1 (en) 2008-10-23
PL1963292T3 (pl) 2012-07-31
KR20080074969A (ko) 2008-08-13
WO2007067615A2 (en) 2007-06-14
IL191549A0 (en) 2008-12-29
BRPI0619600A2 (pt) 2011-10-11
WO2007067615A3 (en) 2007-11-15
MA30202B1 (fr) 2009-02-02
TNSN08249A1 (en) 2009-10-30
AU2006321905A1 (en) 2007-06-14
AU2006321905B2 (en) 2011-08-11
CA2629857A1 (en) 2007-06-14
RU2008127254A (ru) 2010-01-20
UA94724C2 (en) 2011-06-10
AR056838A1 (es) 2007-10-24
CN101326173A (zh) 2008-12-17

Similar Documents

Publication Publication Date Title
ECSP088506A (es) Derivados de tiadiazol como agentes antidiabeticos
ECSP088509A (es) Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EA201100119A1 (ru) Химические соединения 251
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
WO2010074588A8 (en) Pharmaceutical compounds
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EP1819674A4 (en) CONDENSED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008127349A3 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2006084176A3 (en) Compounds and compositions as ppar modulators
MY144970A (en) Heterocyclic compounds
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
DK1824501T3 (da) Proteinhydrolysat med antidiabetisk virkning